trending Market Intelligence /marketintelligence/en/news-insights/trending/BL8l278dRoJdknhIiosrfw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US patent board cancels patent at core of Lipocine, Clarus Therapeutics' dispute

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US patent board cancels patent at core of Lipocine, Clarus Therapeutics' dispute

Lipocine Inc. said the U.S. Patent and Trademark Office canceled a patent at the core of the company's dispute with Clarus Therapeutics Inc.

Both companies have been in a dispute since at least 2016 when Clarus said Lipocine's male testosterone replacement therapy Tlando, or LPCN 1021, infringed on its patent number 8,828,428. However, the U.S. Patent Trial and Appeal Board made a ruling that effectively cancels Clarus' patent.

Lipocine had sought approval of its product in the U.S., but its application was rejected by the U.S. Food and Drug Administration for lack of certain information, including the reliability of certain data related to the medicine's ability to convert testosterone undecanoate — the active ingredient in Tlando — into testosterone.